We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardinal Health (CAH) Tops Q4 Earnings on Strong Revenues
Read MoreHide Full Article
Cardinal Health Inc. (CAH - Free Report) is a healthcare services company engaged in providing pharmaceutical and medical products and services in the United States and International markets. The company primarily operates in two segments, Pharmaceutical and Medical.
Currently, Cardinal Health has a Zacks Rank #4 (Sell) but that could change following its fourth-quarter fiscal 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: Cardinal Health’s adjusted earnings surged 14% on a year-over-year basis to $1.14 per share. It also managed to outpace the Zacks Consensus Estimate of $1.13.
Revenues: Revenues increased 14% on a year-over-year basis to $31.38 billion. It also managed to beat the Zacks Consensus Estimate of $30.67 billion.
Key Stats: Pharmaceutical revenues surged 14% to $28.18 billion while revenues from Medical segment increased 12% to $3.21 billion in the quarter.
Major Factors: Pharmaceutical segment revenues increased due to strong growth from existing and net new distribution customers. Strong performance from the Specialty business also drove results. Higher contributions from acquisitions and strong growth from Cardinal Health brand products were primarily responsible for the growth in Medical segment revenues.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Cardinal Health earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cardinal Health (CAH) Tops Q4 Earnings on Strong Revenues
Cardinal Health Inc. (CAH - Free Report) is a healthcare services company engaged in providing pharmaceutical and medical products and services in the United States and International markets. The company primarily operates in two segments, Pharmaceutical and Medical.
Currently, Cardinal Health has a Zacks Rank #4 (Sell) but that could change following its fourth-quarter fiscal 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: Cardinal Health’s adjusted earnings surged 14% on a year-over-year basis to $1.14 per share. It also managed to outpace the Zacks Consensus Estimate of $1.13.
Revenues: Revenues increased 14% on a year-over-year basis to $31.38 billion. It also managed to beat the Zacks Consensus Estimate of $30.67 billion.
CARDINAL HEALTH Price and EPS Surprise
CARDINAL HEALTH Price and EPS Surprise | CARDINAL HEALTH Quote
Key Stats: Pharmaceutical revenues surged 14% to $28.18 billion while revenues from Medical segment increased 12% to $3.21 billion in the quarter.
Major Factors: Pharmaceutical segment revenues increased due to strong growth from existing and net new distribution customers. Strong performance from the Specialty business also drove results. Higher contributions from acquisitions and strong growth from Cardinal Health brand products were primarily responsible for the growth in Medical segment revenues.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Cardinal Health earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>